MGTA Magenta Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

MGTA [NASD]

Magenta Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.13	Insider Own	16.23%	Shs Outstand	39.61M	Perf Week	-3.56%
Market Cap	341.08M	Forward P/E	-	EPS next Y	-2.01	Insider Trans	18.94%	Shs Float	29.10M	Perf Month	3.98%
Income	-83.30M	PEG	-	EPS next Q	-0.45	Inst Own	73.60%	Short Float	5.51%	Perf Quarter	-5.62%
Sales	-	P/S	-	EPS this Y	33.80%	Inst Trans	0.11%	Short Ratio	7.74	Perf Half Y	-23.87%
Book/sh	4.39	P/B	1.61	EPS next Y	-5.20%	ROA	-49.50%	Target Price	-	Perf Year	-25.00%
Cash/sh	3.65	P/C	1.93	EPS next 5Y	-	ROE	-55.40%	52W Range	5.76 - 16.19	Perf YTD	-53.50%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-56.45%	Beta	-
Dividend %	-	Quick Ratio	17.30	Sales past 5Y	-	Gross Margin	-	52W Low	22.40%	ATR	0.42
Employees	72	Current Ratio	17.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.94	Volatility	5.75% 5.29%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	0.30%	Profit Margin	-	Rel Volume	3.04	Prev Close	7.07
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 06 BMO	Payout	-	Avg Volume	207.15K	Price	7.05
Recom	1.70	SMA20	-1.43%	SMA50	-1.81%	SMA200	-21.14%	Volume	629,963	Change	-0.28%

Jun-08-20

Upgrade

Goldman

Neutral → Buy

$15

Mar-25-19

Downgrade

Goldman

Buy → Neutral

$17 → $16

Mar-15-19

Initiated

Raymond James

Outperform

Jul-16-18

Initiated

Wedbush

Outperform

$22

Jul-16-18

Initiated

JP Morgan

Overweight

$18

Jul-16-18

Initiated

Goldman

Buy

$18

Oct-07-20 12:46PM	Hedge Funds Have Never Been This Bullish On Magenta Therapeutics, Inc. (MGTA) Insider Monkey
Sep-29-20 10:48AM	AVROBIO's Gaucher Disease Candidate Gets Orphan Drug Status Zacks
Sep-11-20 08:00AM	Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in September Business Wire
Sep-02-20 12:00PM	Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV Business Wire
08:00AM	Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operating and Financial Officer Business Wire
Aug-31-20 08:00AM	Magenta Therapeutics Announced It Will Present Clinical and Pre-Clinical Data from Across Immune and Blood System Reset Portfolio at European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting Business Wire +8.02%
Aug-13-20 03:30PM	Wedbush: 3 Healthcare Stocks Under $10 With Massive Upside Ahead TipRanks
Aug-06-20 08:00AM	Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results Business Wire
Aug-04-20 08:28AM	Here's What Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shareholder Ownership Structure Looks Like Simply Wall St.
Aug-03-20 04:05PM	Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August Business Wire
Jul-15-20 07:58PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Magenta Therapeutics, Inc. - MGTA GlobeNewswire
Jul-08-20 03:44PM	Here is What Hedge Funds Think About Magenta Therapeutics, Inc. (MGTA) Insider Monkey
Jul-06-20 05:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA ACCESSWIRE +9.16%
08:40AM	Magenta (MGTA) Looks Good: Stock Adds 5.2% in Session Zacks
Jul-05-20 07:00AM	Big DraftKings Investor Bought Up an Embattled Biotech Stock Barrons.com
Jun-30-20 08:00AM	Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Jun-24-20 08:20PM	Magenta Therapeutics Announces Pricing of Public Offering Business Wire -6.12%
05:46PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA PR Newswire
05:46PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA CNW Group
04:21PM	Magenta Therapeutics Launches Proposed Public Offering Business Wire
Jun-22-20 06:54PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA GlobeNewswire
Jun-20-20 07:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA ACCESSWIRE
Jun-17-20 12:40PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA ACCESSWIRE
Jun-16-20 03:03PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA GlobeNewswire
Jun-15-20 11:00AM	MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Magenta Therapeutics, Inc. and Encourages Investors to Contact the Firm PR Newswire
06:00AM	Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies Business Wire
Jun-13-20 09:09AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA ACCESSWIRE
Jun-12-20 10:45AM	MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Magenta Therapeutics, Inc. and Encourages Investors to Contact the Firm ACCESSWIRE
Jun-11-20 03:09PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA GlobeNewswire -13.12%
07:30AM	Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones Business Wire
07:00AM	Magenta Therapeutics Announces Collaboration with the National Marrow Donor Program/Be The Match to Advance Development of MGTA-145 for First-Line Mobilization of Stem Cells from Healthy Donors and Subsequent Patient Transplant Business Wire
06:47AM	Magenta Therapeutics' Shares March Higher, Can It Continue? Zacks
Jun-08-20 04:30PM	Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences Business Wire
Jun-05-20 08:30AM	Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases Business Wire +7.53%
May-14-20 08:00AM	Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a Phase I Trial Are Effective in Gene Therapy Settings Business Wire
May-07-20 07:30AM	Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results Business Wire
May-06-20 07:00AM	Magenta Therapeutics and AVROBIO Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies Business Wire +10.62%
07:00AM	AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies Business Wire
Apr-30-20 08:00AM	Magenta Therapeutics to Host Business Update Conference Call Business Wire -9.34%
Apr-28-20 04:30PM	Magenta Therapeutics to Present Data from Across Portfolio at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Business Wire -8.42%
Apr-17-20 08:11AM	Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development Business Wire +12.07%
Apr-16-20 08:00AM	Magenta Therapeutics Provides Business Update Business Wire
Apr-07-20 01:21PM	We Think Magenta Therapeutics (NASDAQ:MGTA) Can Afford To Drive Business Growth Simply Wall St.
Mar-03-20 08:00AM	Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights Business Wire -5.36%
Feb-26-20 08:30AM	Magenta Therapeutics to Participate in Cowen Health Care Conference on Monday, March 2nd in Boston Business Wire
Feb-24-20 08:30AM	Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial, Demonstrating Rapid, Single-Day First Line Stem Cell Mobilization and Collection Business Wire -9.21%
08:30AM	Magenta Conditioning Lead Clinical Candidate MGTA-117 Demonstrates Broad Tolerability and High Therapeutic Index in Non-human Primates Business Wire
Feb-20-20 08:30AM	Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy, Demonstrating Continued Durability in Inherited Metabolic Disorders Business Wire +8.21%
Feb-16-20 08:25AM	3 Monster Growth Stocks That Can Charge Forward in 2020 TipRanks
Feb-06-20 08:30AM	Magenta Therapeutics to Participate in Guggenheim Healthcare Talks Oncology Day on Thursday, February 13th in New York City Business Wire
Feb-05-20 08:30AM	Magenta Therapeutics Expands Leadership Team, Appoints Kristen Stants as Chief People Officer and Li Malmberg as Senior Vice President, Head of Manufacturing Business Wire
Jan-13-20 08:00AM	Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals Business Wire -10.83%
Jan-06-20 08:30AM	Magenta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th in San Francisco Business Wire
Dec-19-19 09:54PM	Did Hedge Funds Drop The Ball On Magenta Therapeutics, Inc. (MGTA) ? Insider Monkey
Dec-11-19 09:47AM	Goldman Sachs: The Good, the Bad and the Ugly of the Biotech Sector TipRanks
Dec-09-19 07:45AM	Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate Business Wire
Dec-07-19 05:30PM	First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers Business Wire
08:35AM	The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-01-19 09:30AM	The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
Nov-26-19 04:05PM	Magenta Therapeutics to Present at the Evercore ISI HealthCONx Conference on Tuesday, December 3rd Business Wire -6.06%
Nov-13-19 08:00AM	Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights Business Wire
Nov-11-19 08:30AM	Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR Business Wire
Nov-06-19 09:00AM	Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Meeting Business Wire
Oct-30-19 09:31AM	Magenta Therapeutics, Inc. (MGTA) Is Burning These Hedge Funds Insider Monkey +8.66%
Oct-16-19 08:30AM	Magenta Therapeutics Appoints Jan Pinkas as Senior Vice President, Head of Translational Sciences and Announces Transition of Chief Scientific Officer Business Wire -6.90%
Oct-09-19 08:14AM	Magenta Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-08-19 09:56AM	Did Magenta Therapeutics, Inc. (NASDAQ:MGTA) Insiders Sell Shares? Simply Wall St.
Sep-04-19 08:30AM	Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic Disorders Business Wire
Aug-08-19 08:00AM	Magenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights Business Wire +11.10%
Aug-06-19 08:30AM	Magenta Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13th Business Wire
Jul-12-19 02:29PM	CORRECTING and REPLACING Magenta Therapeutics Appoints Anne McGeorge to Board of Directors Business Wire
Jun-24-19 04:05PM	Magenta Therapeutics Appoints Anne McGeorge to Board of Directors Business Wire -7.47%
Jun-22-19 07:57AM	Can You Imagine How Magenta Therapeutics's (NASDAQ:MGTA) Shareholders Feel About The 12% Share Price Increase? Simply Wall St.
Jun-06-19 04:05PM	Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th Business Wire
May-09-19 08:00AM	Magenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights Business Wire
07:30AM	Magenta Therapeutics Presents Updated Phase 2 Clinical Data on MGTA-456 Cell Therapy at American Academy of Neurology Annual Meeting Business Wire
May-06-19 04:05PM	Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
May-01-19 08:11PM	Magenta Therapeutics Announces Pricing of Public Offering Business Wire
Apr-29-19 04:32PM	Magenta Therapeutics Launches Proposed Public Offering Business Wire
08:00AM	Magenta Therapeutics to Present Preclinical Data on E478 Stem Cell Gene Therapy Expansion Program at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy Business Wire
Apr-24-19 08:30AM	Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate Business Wire +5.54%
Apr-07-19 06:00PM	3 Stocks That Have More Than Tripled So Far in 2019 Motley Fool
Mar-20-19 12:07PM	Raymond James Thinks Magenta Still Has Upside GuruFocus.com
Mar-19-19 07:30AM	Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights Business Wire
Mar-15-19 01:32PM	How Many Insiders Bought Magenta Therapeutics, Inc. (NASDAQ:MGTA) Shares? Simply Wall St. +26.19%
Mar-06-19 04:05PM	Magenta Therapeutics to Present at Investor Conferences in March Business Wire
Feb-25-19 08:15AM	Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate Business Wire +12.03%
08:15AM	Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting Business Wire
Feb-21-19 08:00AM	Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant Business Wire -5.66%
Feb-07-19 08:30AM	Magenta Therapeutics to Present at Guggenheim Healthcare Investor Conference Business Wire
Jan-02-19 08:30AM	Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 Business Wire +5.26%
Dec-02-18 09:00PM	Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit Business Wire
09:00PM	Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders Business Wire
Dec-01-18 12:30PM	Magenta Therapeutics Presents New Preclinical Data on MGTA-145 Stem Cell Mobilization Product Candidate Business Wire
Nov-26-18 08:30AM	Magenta Therapeutics to Host Webcast of Investor and Analyst Event During ASH Business Wire
Nov-19-18 08:00AM	Magenta Therapeutics Appoints Jason Ryan as Chief Operating and Financial Officer Business Wire
Nov-08-18 08:00AM	Magenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results Business Wire
Nov-01-18 09:00AM	Magenta Therapeutics Announces Acceptance of Nine Abstracts Covering Clinical and Preclinical Data at ASH, Representing Progress across the Portfolio of Conditioning, Stem Cell Mobilization and Expansion Programs Business Wire -5.82%
Sep-24-18 08:30AM	Magenta Therapeutics Added to Russell 2000 and 3000 Indexes Business Wire +5.92%
Aug-09-18 04:05PM	Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results Business Wire

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Booth Bruce	Director	Jun 29	Buy	8.00	1,250,000	10,000,000	1,250,000	Jul 01 04:48 PM
GARDNER JASON	See Remarks	Jan 10	Sale	15.25	11,200	170,800	251,212	Jan 10 05:01 PM
DAVIS JOHN C. JR	Chief Medical Officer	Jan 02	Option Exercise	9.49	11,294	107,180	19,598	Jan 03 04:01 PM
GARDNER JASON	See Remarks	Jan 02	Sale	15.10	2,800	42,280	262,412	Jan 03 04:01 PM
DAVIS JOHN C. JR	Chief Medical Officer	Jan 02	Sale	15.04	11,294	169,817	8,304	Jan 03 04:01 PM
ZDRAVESKI ZORAN	See Remarks	Dec 24	Sale	16.00	7,902	126,432	128,009	Dec 26 04:11 PM
ISACSON CHRISTINA K.	Chief Business Officer	Dec 24	Sale	16.01	4,463	71,453	83,786	Dec 26 04:12 PM
ISACSON CHRISTINA K.	Chief Business Officer	Dec 23	Sale	16.03	9,867	158,168	88,249	Dec 26 10:12 AM
ZDRAVESKI ZORAN	See Remarks	Dec 23	Sale	16.03	4,181	67,021	135,911	Dec 26 10:13 AM
GARDNER JASON	See Remarks	Dec 23	Sale	15.10	2,897	43,755	265,212	Dec 23 04:41 PM
DAVIS JOHN C. JR	Chief Medical Officer	Dec 20	Option Exercise	9.49	919	8,721	9,223	Dec 20 05:52 PM
GARDNER JASON	See Remarks	Dec 20	Sale	15.16	76,711	1,162,617	268,109	Dec 20 06:22 PM
DAVIS JOHN C. JR	Chief Medical Officer	Dec 20	Sale	15.00	919	13,785	8,304	Dec 20 05:52 PM
DAVIS JOHN C. JR	Chief Medical Officer	Dec 10	Option Exercise	9.49	17,055	161,852	25,359	Dec 11 04:03 PM
DAVIS JOHN C. JR	Chief Medical Officer	Dec 10	Sale	15.00	17,055	255,825	8,304	Dec 11 04:03 PM
GARDNER JASON	See Remarks	Dec 10	Sale	15.10	4,392	66,319	344,820	Dec 13 05:08 PM
DAVIS JOHN C. JR	Chief Medical Officer	Dec 09	Option Exercise	9.49	4,614	43,787	12,918	Dec 11 04:03 PM
DAVIS JOHN C. JR	Chief Medical Officer	Dec 09	Sale	15.00	4,614	69,210	8,304	Dec 11 04:03 PM
COOKE MICHAEL P.	Chief Scientific Officer	Dec 02	Sale	13.00	7,500	97,520	240,523	Dec 02 08:29 PM
COOKE MICHAEL P.	Chief Scientific Officer	Nov 20	Sale	12.00	5,000	60,000	248,023	Nov 25 08:52 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience